Table 2.
The proportion of participants with simultaneous positive responses to ≥2 cytokines
| LZ901 group n/N (%) | HZ/su group n/N(%) | Difference % (95% CI) (LZ901 vs. HZ/su) | p value | |
|---|---|---|---|---|
| The proportion of CD42+ T-cell responders | ||||
| All age | 117/141 (83.0) | 79/136 (58.1) | 24.9 (14.5,35.3) | <0.0001 |
| 50–59 years | 57/73 (78.1) | 42/73 (57.5) | 20.6 (5.8,34.5) | <0.0001 |
| 60–69 years | 47/52 (90.4) | 29/50 (58.0) | 32.4 (12.6,52.2) | <0.0001 |
| ≥70 years | 13/16 (81.3) | 8/13 (61.5) | 32.6 (−12.9,52.3) | 0.03719 |
| The proportion of CD82+ T-cell responders | ||||
| All age | 66/141 (46.8) | 12/136 (8.8) | 38.0 (28.5,47.5) | <0.0001 |
| 50–59 years | 36/73 (49.3) | 4/73 (5.5) | 43.8 (31.2,56.5) | <0.0001 |
| 60–69 years | 22/52 (42.3) | 6/50 (12.0) | 30.3 (14.1,46.5) | <0.0001 |
| ≥70 years | 8/16 (50.0) | 2/13 (15.4) | 34.6 (3.2,66.0) | 0.00267 |
N = the number of participants included in the analysis; n = the number of participants with simultaneous positive responses to ≥2 cytokines (referred to as gE-specific CD42+/CD82+ T-cell responses; For each cytokine (IFN-γ, IL-2, TNF-α, or CD40L), a positive responder was defined as a 2-fold increase in cytokine-secreting T cells post-vaccination compared to pre-vaccination levels. In HZ/su group, there was one sample from each of 50–59 years and 60–69 years group that could not be tested due to insufficient cell quantity; 95% CIs of the rate difference were calculated using the Miettinen and Nurminen method, two-sided χ2 test or Fisher’s exact test was used for comparisons between two groups.